Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of BAY1817080 in Healthy Men
NCT02817100Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic cough, endometriosis, overactive bladder (OAB) and 1 more comparing BAY1817080 with Placebo (2 arms). Primary endpoints: Frequency of treatment-emergent adverse events up to 4 months and Severity of treatment-emergent adverse events up to 4 months. Started Jul 2016; status: completed.
02
Drugs
eliapixant
03
Conditions
chronic coughendometriosisoveractive bladder (OAB)neuropathic pain
Beyond the preview
Go deeper on NCT02817100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817100.